Is a repeat fluid draw needed to treat spontaneous bacterial peritonitis?
Tests routine repeat belly fluid checks in spontaneous bacterial peritonitis.
Key facts
- Who runs it
- Chonnam National University Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 4 Oct 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Routine Follow-up Paracentesis at 48 Hours
- Other
- Record updated
- 6 November 2026
Who can take part
The trial is looking for adults with liver cirrhosis who have spontaneous bacterial peritonitis, an infection of the fluid in the belly. It compares a routine repeat fluid test at about 48 hours with no routine repeat test.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Liver cirrhosis, shown by clinical, tissue or imaging findings, with spontaneous bacterial peritonitis.
- Biomarker or test result
- Belly fluid white cell (PMN) count of ≥250 cells/mm³ at the first fluid draw (paracentesis).
- Main reasons for not taking part
- Suspected peritonitis from another cause, such as a hole in the gut
- Cannot safely have a fluid draw: platelet count <20,000/mm³ or PT-INR >3.0
- Active bleeding or shock, or expected survival of less than 48 hours
- Pregnancy or breastfeeding
- Earlier culture showing resistance to cefotaxime or ceftriaxone
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Adults aged 18 years or older
- Diagnosis of liver cirrhosis based on clinical, histologic, or imaging findings
- Diagnosis of spontaneous bacterial peritonitis confirmed by an ascitic fluid polymorphonuclear leukocyte (PMN) count of ≥250 cells/mm³ at initial paracentesis
- Ability and willingness to provide written informed consent
Who cannot take part
- Previous ascitic fluid or blood culture demonstrating resistance to cefotaxime or ceftriaxone
- Suspected secondary bacterial peritonitis, including suspected perforation of a gastrointestinal organ
- Active bleeding or shock
- Any other condition that, in the investigator's judgment, would prevent adherence to the study protocol
- Inability to safely undergo paracentesis, defined as platelet count <20,000/mm³ or prothrombin time international normalized ratio (PT-INR) >3.0
- Expected survival of less than 48 hours
- Pregnancy or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Spontaneous bacterial peritonitis (SBP) is a serious infection that occurs in patients with liver cirrhosis and ascites and is associated with substantial morbidity and mortality. Current clinical practice often includes follow-up paracentesis approximately 48 hours after starting antibiotic treatment to assess the change in the ascitic fluid polymorphonuclear leukocyte (PMN) count. However, it remains uncertain whether routine follow-up paracentesis improves clinical outcomes compared with a strategy based primarily on clinical response.
Read full original descriptionShow less
This pilot randomized controlled trial will evaluate whether routine follow-up paracentesis is necessary in patients with cirrhosis and SBP. A total of 40 adult patients with SBP will be randomly assigned in a 1:1 ratio to either a routine follow-up paracentesis group or a no-routine follow-up paracentesis group. All participants will receive standard antibiotic therapy and intravenous albumin according to the study protocol.
Participants assigned to the routine follow-up paracentesis group will undergo repeat paracentesis approximately 48 hours after initiation of antibiotic therapy. Ascitic fluid PMN counts and other laboratory findings will be assessed, and antibiotic treatment may be modified according to the treatment response. Participants assigned to the no-routine follow-up paracentesis group will be monitored using clinical symptoms, vital signs, and blood inflammatory markers without scheduled repeat paracentesis. However, paracentesis may be performed at any time if clinically indicated, such as in the presence of worsening abdominal symptoms, persistent fever, or hemodynamic instability.
The study will compare clinical outcomes between the two treatment strategies, including 30-day and 90-day survival, treatment response, duration of antibiotic therapy, length of hospital stay, SBP recurrence, complications, new infections, and medical costs. The results of this pilot study are intended to provide preliminary evidence for determining whether routine follow-up paracentesis can be safely avoided in selected patients with SBP and to inform the design of a larger randomized controlled trial.
The 2 groups in the trial
- A (Routine Follow-up Paracentesis)Treatment being tested
Routine follow-up paracentesis approximately 48 hours after initiation of antibiotic therapy.
Treatment: Routine Follow-up Paracentesis at 48 Hours
- B (No Routine Follow-up Paracentesis)Existing treatment, for comparison
No routine follow-up paracentesis; paracentesis will be performed only when clinically indicated.
Treatment: Other
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Study of Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis in Liver Cirrhosis: A Pilot Study
- Plain-language title
- Is a repeat fluid draw needed to treat spontaneous bacterial peritonitis?Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07923318, who can take part
- Record updated
- 6 November 2026